Research Projects & Grants

For Profit Organization

  • A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants with Advanced Parkinson's Disease. PD0060, Role: Investigator, UCB Biopharma SPRL, (03/2025 - 03/2026) Status: Approved
  • RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion assess sustained effecTs of dRoxidopa therapy, Role: Investigator, Lundbeck Inc., (02/2022 - 02/2023) Status: Completed
  • A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy, Role: Investigator, U.S. World Meds, (11/2021 - 11/2022) Status: Completed
  • A Phase 3, open-label, multi-center trial to evaluate the long-term safety and efficacy of repeat treatment of DaxibotulinumtoxinA for injection in adult with isolated cervical dystonia (ASPEN-OLS). Protocol: 1720304, Role: Investigator, Revance Therapeutics, Inc., (04/2021 - 04/2022) Status: Completed
  • A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multi-center trial to evaluate the efficacy and safety of a single treatment of DaxibotulinumtoxinA for injection in adults with isolated cervical dystonia (ASPEN-1). Protocol: 1720302, Role: Investigator, Revance Therapeutics, Inc., (11/2019 - 11/2020) Status: Completed
  • A phase III multi-center randomized double-bind double-dummy active-controlled study comparing the efficacy and safety of gastric retentive controlled release accordion pill™ carbidopa/levodopa (AP-CD/LD) to immediate release CD/LD in fluctuating Parkinson's Disease patients Protocol Number: IN 11004, Role: Investigator, Intec Pharma Ltd., (04/2019 - 04/2020) Status: Completed
  • Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017, Role: Investigator, Allergan Inc., (08/2018 - 08/2019) Status: Completed
  • A phase 3, multicenter, randomized, double-blinded, placebo controlled study with an open label phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson's Disease experiencing end of dose "wearing off" (TOZ-PD). Protocol #: TOZ-CL05, Role: Investigator, Biotie Therapies Inc, (07/2017 - 07/2018) Status: Completed
  • A phase 3, long-term, open-label and single-arm study of MYOBLOC® in the treatment of troublesome sialorrhea in adult subjects. Protocol Number: SN-SIAL-351, Role: Investigator, U.S. World Meds, (03/2017 - 03/2018) Status: Completed
  • A phase 3, multi-center, double-blind, placebo-controlled, single-treatment efficacy and safety study of MYOBLOC® (Part A) followed by open-label, multiple-treatment with MYOBLOC® (Part B) in the treatment of troublesome Sialorrhea in adult subjects. Protocol number: SN-SIAL-301, Role: Investigator, U.S. World Meds, (12/2016 - 12/2017) Status: Completed
  • A Multicenter, Interventional, Post-marketing, Randomized, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity. Protocol: CLIN-52120-452, Role: Investigator, Ipsen Pharma SAS, (11/2024 - 11/2025) Status: Approved

Internal

  • MRI Evidence of Increased Iron Deposition in the Basal Ganglia of Patients Admitted for Stroke with a History of Methamphetamine Use: A Prevalence Study, Role: Investigator, LLU Dept. of Neurology, (09/2023) Status: Approved
  • Does cannabis induce psychosis in Parkinson's disease patients?, Role: Investigator, LLU Dept. of Neurology, (02/2019 - 09/2024) Status: Completed

Non-Profit Organization

  • An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability Of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease, Role: Investigator, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved
  • A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® for the Treatment of Upper Limb Essential Tremor. Protocol: M21-471, Role: Investigator, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved